Cosmetic neurology: The controversy over enhancing movement, mentation, and mood

Neurology

Volumn 63, Issue 6, 2004, Pages 968-974

  Chatterjee, Anjan ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMPA RECEPTOR AGONIST; AMPAKINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; ERYTHROPOIETIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYPERICUM PERFORATUM EXTRACT; KAVA; METHYLPHENIDATE; MODAFINIL; PARACETAMOL; PAROXETINE; PROPRANOLOL; ROLIPRAM; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; SOMATOMEDIN; STEROID; UNCLASSIFIED DRUG; VALERIAN;

BRAIN FUNCTION; COGNITION; ESTHETICS; HUMAN; MOOD; NEUROLOGY; NEUROMODULATION; NEUROPHARMACOLOGY; NEUROSCIENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; THINKING;

EID: 4644325547     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000138438.88589.7C     Document Type: Review

References (66)

1. Groopman J. Eyes wide open. The New Yorker 2001;December 3:52-57.
2. Marcus S. Neuroethics: Mapping the Field: Dana Press, 2002.
3. Rose S. Smart drugs: do they work, will they be legal. Nature Reviews Neuroscience 2002;3:975-979.
4. The ethics of brain science. Open your mind. The Economist, May 2002;25:77-79.
5. Farah MJ. Emerging ethical issues in neuroscience. Nature Neuroscience 2002;5:1123-1129.
6. Wolpe P. Treatment, enhancement, and the ethics of neurotherapeutics. Brain Cogn 2002;50:387-395.
7. Plotz D. The ethics of enhancement. Slate, March 12, 2003. Available at: http://slate.msn.com/id/2079310/.
8. Elliott C. American bioscience meets the American dream. The American Prospect 2003;14:38-42.
9. President's Council on Bioethics. Beyond Therapy: Biotechnology and the Pursuit of Happiness, 2003. Available at: http://bioethics.gov/reports/ beyondtherapy/index.html.
10. Bailey R. The battle for your brain. Reason online, February 2003. Available at: http://reason.com/0302/fe.rb.the.shtml.
11. Whitehouse P, Juengst E, Mehlman M, Murray T. Enhancing cognition in the intellectually intact. Hastings Cent Rep 1997;May-June:14-22.
12. Harris I. The impact of Parkinson's disease on quality of life, 2003. Available at: http://www.amarinpharma.com/pdfs/ HarrisInteractive_Parkinson_toplineReport_102003.pdf.
13. Nortvedt M, Riise T. The use of quality of life measures in multiple sclerosis research. Mult Scler 2003;9:63-72.
14. Fukayama F. Our Posthuman Future. New York: Farrar, Straus & Giroux, 2002.
15. Guttler L, Silvers J, Singh J, et al. Short stature and growth hormone therapy: a national study of physician recommendation patterns. JAMA 1996;276:531-537.
16. Daniels N. Normal functioning and the treatment-enhancement distinction. Cambridge Quarterly 2000;9:309-322.
17. Rudman D, Feller A, Nagraj H, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990;323:1-6.
18. Barton-Davis E, Shoturma D, Musaro A, Rosenthal N, Sweeney H. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci USA 1998;95:15603-15607.
19. Gaudard A, Varlet-Marie E, Bressolle F, Audran M. Drugs for increasing oxygen transport and their potential use in doping. Sports Med 2003;33:187-212.
20. Varlet-Marie E, Gaudard A, Audran M, Bressolle F. Pharmacokinetics/ pharmacodynamics of recombinant human erythropoietins in doping control. Sports Med 2003;33:301-315.
21. Walker-Batson D, Smith P, Curtis S, Unwin H, Greenlee R. Amphetamine paired with physical therapy accelerates motor recovery after stroke: further evidence. Stroke 1995;26:2254-2259.
22. Grade C, Redford B, Chrostowski J, Toussaint L, Blackwell B. Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. Arch Phys Med Rehabil 1998;79:1047-1050.
23. Walker-Batson D, Curtis S, Natarajan R, et al. A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. Stroke 2001;32:2093-2098.
24. Lagarde D, Batejat D, Van Beers P, Sarafian D, Pradella S. Interest of modafinil, a new psychostimulant, during a sixty-hour sleep deprivation experiment. Func Clin Pharmacol 1995;9:1-9.
25. Caldwell JJ, Caldwell J, Smythe NR, Hall K. A double-blind, placebo-controlled investigation of the efficacy of modafinil for sustaining the alertness and performance of aviators: a helicopter simulator study. Psychopharmacology 2000;150:272-282.
26. Pary R, Lewis S, Matuschka P, Rudzinskiy P, Safi M, Lippman S. Attention deficit disorder in adults. Ann Clin Psychiatry 2002;14:105-111.
27. Weber P, Lutschg J. Methylphenidate treatment. Pediatr Neurol 2002;26:261-266.
28. Diller L. The run on Ritalin: attention deficit disorder and stimulant treatment in the 1990s. Hastings Cent Rep 1996;26:12-14.
29. Babcock Q, Byrne T. Student perceptions of methylphenidate abuse at a public liberal arts college. J Am College Health 2000;49:143-145.
30. Yesavage J, Mumenthaler M, Taylor J, et al. Donezepil and flight simulator performance: effects on retention of complex skills. Neurology 2001;59:123-125.
31. Hall S. The quest for a smart pill. Sci Am 2003;289:54-65.
32. Kemp J, McKernan R. NMDA receptor pathway as drug targets. Nature Neuroscience 2002;5 Suppl:1039-1042.
33. Lynch G. Memory enhancement: the search for mechanism-based drugs. Nature Neuroscience Supplement 2003;5:1035-1038.
34. Granger R, Deadwyler S, Davis M, et al. A drug that facilitates glutamergic transmission reduces exploratory activity and improves performance in a learning dependent task. Synapse 1993;15:326-329.
35. Staubli U, Rogers G, Lynch G. Facilitation of glutamate receptors enhances memory. Proc Natl Acad Sci USA 1994;91:777-781.
36. Ingvar M, Ambros-Ingerson J, Davis M, et al. Enhancement by an ampakine of memory encoding in humans. Exp Neurol 1997;146:553-559.
37. Tang Y-P, Shimizy E, Dube G, et al. Genetic enhancement of learning and memory in mice. Nature 1999;401:63-69.
38. Tully T, Bourtchouladze R, Scott R, Tallman J. Targeting the CREB pathway for memory enhancers. Nature Reviews Drug Discovery 2003;2:267-277.
39. Yin J, Del Vecchio M, Zhou H, Tully T. CREB as memory modulator: induced expression of a dCREB2 activator isoform enhances long-term memory in Drosophila. Cell 1995;81:105-115.
40. Scott R, Bourtchouladze R, Gossweiler S, Dubnau J, Tully T. CREB and the discovery of cognitive enhancers. J Mol Neurosci 2002;19:171-177.
41. National Institute of Mental health. The numbers count: mental disorders in America. Washington, DC, 2003. Available at: http://www.nimh.nih.gov/ publicat/numbers.cfm.
42. Kramer P. Listening to prozac. New York: Penguin, 1993.
43. Knutson B, Wolkowitz O, Cole S, et al. Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatry 1998;155:333-339.
44. Tse W, Bond A. Serotonergic intervention affects both social dominance and affiliative behavior. Psychopharmacology 2002;161:373-379.
45. Salzano J. Taming stress. Scientific American 2003;289:87-95.
46. Holmes A, Heilig M, Rupniak N, Steckler T, Griebel G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 2003;24:580-588.
47. Davis M. Are different parts of the extended amygdala involved in fear versus anxiety? Biol Psychiatry 1998;44:1239-1247.
48. Walker D, Toufexis D, Davis M. Role of the bed nucleus of the stria terminalis versus amygdala in fear, stress, and anxiety. Eur J Pharmacol 2003;463:199-216.
49. George M. Stimulating the brain. Sci Am 2003;289:67-77.
50. George M, Wasserman E, Williams W, et al. Daily repetitive transcranial stimulation (rTMS) improves mood in depression. Neuroreport 1995;6:1853-1856.
51. Cahill L. Similar neural mechanisms for emotion-induced memory impairment and enhancement. Proc Natl Acad Sci USA 2003;100:13123-13124.
52. Cahill L, Prins B, Weber M, McGaugh J. Beta-adrenergic activation and memory for emotional events. Nature 1994;371:702-704.
53. Strange B, Hurlemann R, Dolan R. An emotion-induced retrograde amnesia in humans is amygdala- and β-adrenergic-dependent. Proc Natl Acad Sci USA 2003;100:13626-13631.
54. Pitman R, Sanders K, Zusman R, et al. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry 2002;51:189-192.
55. Tang Y-P, Shimizu E, Tsien J. Do 'smart' mice feel more pain, or are they just better learners. Nature Neuroscience 2001;4:453-454.
56. Baron J. Thinking and Deciding. New York: Cambridge University Press, 1994.
57. Kass L. The pursuit of biohappiness. Washington Post, October 16, 2003;Sect. A25.
58. Elliott C. Better than Well: American Medicine Meets the American Dream. New York: WW Norton & Company, 2003.
59. Frank R. Choosing the Right Pond. New York: Oxford Press, 1987.
60. Caplan A. Is better best? Sci Am 2003;289:104-105.
61. Frank R, Cook P. The Winner-Take-All Strategy. New York: The Free Press, 1995.
62. Solomon P, Adams F, Silver A, Zimmer J, DeVeaux R. Ginkgo for memory enhancement: a randomized controlled trial. JAMA 2002;288:835-840.
63. Langreth R. Viagra for the brain. Forbes, February 2002. Available at: http://www.forbes.com/forbes/2002/0204/046.html.
64. Seligman M. Authentic Happiness: Using the New Positive Psychology to Realize Your Potential for Lasting Fulfillment. New York: Free Press/Simon and Shuster, 2002.
65. Schneider C. The Practice of Autonomy: Patients, Doctors and Medical Decisions. New York: Oxford Press, 1998.
66. Schwartz B. The Paradox of Choice: Why Less Is More. New York: Ecco, 2004.